Cancer Immunotherapy Global Market Overview 2023-2030, Competitive Analysis of Amgen, AstraZeneca,Bayer, BMS, Eli Lilly, F. Hoffmann-La Roche, GSK, Immunocore, J&J, Merck, Novartis, Pfizer
January 10, 2025 04:06 ET
|
Research and Markets
Dublin, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering.The global market for Cancer Immunotherapy...
Cancer Immunotherapy Market Research Report 2025-2029: Curing Cancer is Generating Enormous New Markets - How Big Are They? Where is the Opportunity?
December 26, 2024 04:13 ET
|
Research and Markets
Dublin, Dec. 26, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Market 2025-2029 - Forecasts for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer, with Executive and Consultant...
Immuno-Oncology Strategic Industry Research Report 2023-2024 & 2030: Approval of Pembrolizumab (Keytruda) and Nivolumab (Opdivo), which Target PD-1 and PD-L1 Pathways have Set New Benchmarks
December 05, 2024 10:16 ET
|
Research and Markets
Dublin, Dec. 05, 2024 (GLOBE NEWSWIRE) -- The "Immuno-Oncology - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Immuno-Oncology...
Cancer Immunotherapy Strategic Research Business Report 2023-2030: Improved Delivery Systems, Desire for Non-Toxic Treatments, Checkpoint Inhibitors Spur New Developments and Growth
December 04, 2024 10:55 ET
|
Research and Markets
Dublin, Dec. 04, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Cancer...
Cancer Immunotherapy Drug Discovery Outsourcing Strategic Business Report 2024: Global Market to Reach $4 Billion by 2030, Driven by Trends in Global Expansion to Tap into Emerging Markets
December 02, 2024 07:32 ET
|
Research and Markets
Dublin, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Drug Discovery Outsourcing - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The...
Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition in murine models of breast, colorectal, and prostate cancers
November 08, 2024 14:51 ET
|
Io Therapeutics, Inc.
Io Therapeutics, Inc., presents data on IRX5010 showing inhibition of tumor infiltrating T-cells and myeloid derived suppressor cells in multiple cancers
Cancer Immunotherapy Market Research 2024-2032: Personalized Cancer Vaccines and CAR T Cell Therapy Revolutionize Immunotherapy
October 07, 2024 07:18 ET
|
Research and Markets
Dublin, Oct. 07, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Market Report, Forecast by Products, Application, End Users, Countries and Company Analysis, 2024-2032" report has been added to ...
Groundbreaking Market Report Forecasts Significant Growth in Cancer Immunotherapy by 2027
September 19, 2024 09:41 ET
|
Research and Markets
Dublin, Sept. 19, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Markets. The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics by Therapy, by Cancer and by Customer...
ImmunOs Therapeutics AG Raises $11 Million and Further Strengthens Investor Base
September 17, 2024 04:00 ET
|
AKAMPION
Existing investors and new investor Double Point Ventures join forces to support ImmunOs TherapeuticsInvestment secures funding of ongoing promising clinical trial of IOS-1002 in solid cancers ...
India Liver Cancer Therapeutics Research Report 2024-2030 Featuring Natco Pharma, Dr. Reddy's Laboratories, Intas Pharmaceuticals, Mylan Pharmaceuticals, Lupin, Biocon, and Hetero Labs
September 11, 2024 11:54 ET
|
Research and Markets
Dublin, Sept. 11, 2024 (GLOBE NEWSWIRE) -- The "India Liver Cancer Therapeutics Market, By Region, Competition, Forecast & Opportunities, 2020-2030F" report has been added to ...